HRP20191664T1 - Sastavi i postupci za moduliranje ekspresije komplementa faktora b - Google Patents
Sastavi i postupci za moduliranje ekspresije komplementa faktora b Download PDFInfo
- Publication number
- HRP20191664T1 HRP20191664T1 HRP20191664T HRP20191664T1 HR P20191664 T1 HRP20191664 T1 HR P20191664T1 HR P20191664 T HRP20191664 T HR P20191664T HR P20191664 T1 HRP20191664 T1 HR P20191664T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- modified
- segment
- wing
- modified oligonucleotide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 4
- 102000003712 Complement factor B Human genes 0.000 title 1
- 108090000056 Complement factor B Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 108091034117 Oligonucleotide Proteins 0.000 claims 14
- 239000002777 nucleoside Substances 0.000 claims 8
- 125000003835 nucleoside group Chemical group 0.000 claims 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 2
- 208000016323 C3 glomerulonephritis Diseases 0.000 claims 2
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 208000022401 dense deposit disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 230000003831 deregulation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21047—Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (14)
1. Spoj koji sadrži modificirani oligonukleotid i konjugiranu skupinu, gdje modificirani oligonukleotid se sastoji od 20 do 30 vezanih nukleozida i ima nukleobaznu sekvencu SEQ ID NO: 440, gdje je oligonukleotid bar 80% komplementaran sa SEQ ID NO: 1 ili 2 i gdje konjugirana skupina obuhvaća:
2. Spoj prema zahtjevu 1, gdje modificirani oligonukleotid sadrži barem jednu modificiranu internukleozidnu vezu, barem jedan modificirani šećer, ili barem jednu modificiranu nukleobazu, opcionalno gdje modificirana internukleozidna veza je fosforotioatna internukleozidna veza.
3. Spoj prema zahtjevu 2, gdje modificirani oligonukleotid sadrži:
a) barem 1 fosforodiestersku internukleozidnu vezu;
b) barem 2 fosforodiesterske internukleozidne veze;
c) barem 3 fosforodiesterske internukleozidne veze;
d) barem 4 fosforodiesterske internukleozidne veze;
e) barem 5 fosforodiesterskih internukleozidnih veza;
f) barem 6 fosforodiesterskih internukleozidnih veza; ili
g) barem 7 fosforodiesterskih internukleozidnih veza,
opcionalno gdje:
i) svaka internukleozidna veza modificiranog oligonukleotida je izabrana iz fosforodiesterske internukleozidne veze i fosforotioatne internukleozidne veze; ili
ii) svaka internukleozidna veza modificiranog oligonukleotida sadrži fosforotioatnu internukleozidnu vezu.
4. Spoj prema zahtjevu 2 ili 3, gdje:
a) modificirani šećer je biciklički šećer, opcionalno gdje je biciklički šećer izabran iz skupine koju čine: 4’-(CH2)-O-2’ (LNA); 4’-(CH2)2-O-2’ (ENA); i 4’-CH(CH3)-O-2’ (cEt); ili
b) modificirani šećer je 2’-O-metoksietil; i/ili
c) modificirana nukleobaza je 5-metilcitozin.
5. Spoj prema bilo kojem od zahtjeva 1-4, gdje modificirani oligonukleotid sadrži:
(a) segment praznine koji se sastoji od povezanih deoksinukleozida;
(b) 5’ segment „krila“ koji se sastoji od povezanih nukleozida; i
(c) 3’ segment „krila“ koji se sastoji od povezanih nukleozida;
gdje segment praznina je smješten odmah pored i između 5’ segmenta „krila“ i 3’ segmenta „krila“ i gdje svaki nukleozid svakog segmenta „krila“ sadrži modificirani šećer.
6. Spoj prema zahtjevu 5, gdje modificirani oligonukleotid se sastoji od 20 povezanih nukleozida koji imaju nukleobaznu sekvencu koja se sastoji od sekvence navedene u SEQ ID NO: 440, gdje modificirani oligonukleotid sadrži
segment praznina koji se sastoji od deset povezanih deoksinukleozida;
5’ segment "krila" koji se sastoji od pet povezanih nukleozida; i
3’ segment „krila“ koji se sastoji od pet povezanih nukleozida;
gdje segment razmaka je smješten između 5’ segmenta „krila“ i 3’ segmenta „krila“, gdje svaki nukleozid svakog segmenta „krila“ se sastoji od 2’-O-metoksietil šećera; gdje svaka internukleozidna veza je fosforotioatna veza i gdje svaki citozin je 5-metilcitozin.
7. Spoj prema bilo kojem od zahtjeva 1-5, gdje je oligonukleotid bar 85%, 90%, 95% ili 100% komplementaran sa SEQ ID NO: 1 ili 2.
8. Spoj prema bilo kojem od zahtjeva 1-7, gdje:
a) spoj je jednolančan; ili
b) spoj je dvolančan; i/ili
c) spoj sadrži:
i) ribonukleotide; ili
ii) deoksiribonukleotide.
9. Spoj prema bilo kojem od zahtjeva 1-8, gdje konjugirana skupina je povezana s modificiranim oligonukleotidom:
i) na 5’ kraju modificiranog oligonukleotida; ili
ii) na 3’ kraju modificiranog oligonukleotida.
10. Spoj prema zahtjevu 1 koji ima formulu:
a)
gdje ili R1 je -OCH2CH2OCH3 (MOE) i R2 je H; ili R1 i R2 zajedno tvore most, gdje R1 je -O- i R2 je -CH2-, -CH(CH3)-, ili -CH2CH2-, i R1 i R2 su direktno povezani tako da je tako dobiveni most izabran između : -O-CH2-, -O-CH(CH3)-, i -O-CH2CH2-;
i za svaki par R3 i R4 na istom prstenu, neovisno od svakog prstena : ili R3 je izabran između H i -OCH2CH2OCH3 i R4 je H; ili R3 i R4 zajedno tvore most, gdje R3 je -O-, i R4 je-CH2-, -CH(CH3)-, ili -CH2CH2- i R3 i R4 su direktno povezani tako da je dobiveni most izabran između : -O-CH2-, -O-CH(CH3)-, i -O-CH2CH2-;
i R5 je izabran između H i -CH3;
i Z je izabran između S- i O-;
b)
c)
ili d)
11. Spoj prema zahtjevu 1 koji ima formulu:
12. Sastav koji sadrži spoj prema bilo kojem od zahtjeva 1-11 ili njegova sol i barem jedan farmaceutski prihvatljiv nosač ili razrjeđivač.
13. Spoj prema bilo kojem od zahtjeva 1-11 ili sastav prema zahtjevu 12 za upotrebu u liječenju, prevenciji ili ublažavanju bolesti u vezi s deregulacijom alternativnog puta komplementa kod subjekta.
14. Spoj ili sastav za upotrebu prema zahtjevu 13, gdje je bolest:
a) makularna degeneracija, starosna makularna degeneracija (AMD), vlažna AMD, suha AMD ili geografska atrofija;
b) bolest bubrega, opcionalno gdje je bolest lupus nefritis, sistemski eritemski lupus (SLE), bolest gustih naslaga (DDD), C3 glomerulonefritis (C3GN), CFHR5 nefropatija ili atipični hemolitičko-uremički sindrom (aHUS).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461987471P | 2014-05-01 | 2014-05-01 | |
US201462076273P | 2014-11-06 | 2014-11-06 | |
EP15786214.5A EP3137596B1 (en) | 2014-05-01 | 2015-05-01 | Compositions and methods for modulating complement factor b expression |
PCT/US2015/028916 WO2015168635A2 (en) | 2014-05-01 | 2015-05-01 | Compositions and methods for modulating complement factor b expression |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191664T1 true HRP20191664T1 (hr) | 2019-12-13 |
Family
ID=54359510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191664 HRP20191664T1 (hr) | 2014-05-01 | 2019-09-16 | Sastavi i postupci za moduliranje ekspresije komplementa faktora b |
Country Status (29)
Country | Link |
---|---|
US (4) | US10280423B2 (hr) |
EP (3) | EP3137596B1 (hr) |
JP (2) | JP6637442B2 (hr) |
KR (1) | KR102369736B1 (hr) |
CN (2) | CN110724687B (hr) |
AU (1) | AU2015252858C1 (hr) |
BR (1) | BR112016022593B1 (hr) |
CA (1) | CA2943894A1 (hr) |
CL (2) | CL2016002764A1 (hr) |
CR (2) | CR20200228A (hr) |
DK (1) | DK3137596T3 (hr) |
DO (1) | DOP2016000291A (hr) |
EA (1) | EA036496B1 (hr) |
ES (2) | ES2941742T3 (hr) |
HR (1) | HRP20191664T1 (hr) |
HU (1) | HUE046272T2 (hr) |
IL (2) | IL247883B (hr) |
LT (1) | LT3137596T (hr) |
MX (1) | MX2016014294A (hr) |
PE (2) | PE20170010A1 (hr) |
PH (1) | PH12016502062A1 (hr) |
PL (2) | PL3608406T3 (hr) |
PT (1) | PT3137596T (hr) |
RS (1) | RS59182B1 (hr) |
RU (1) | RU2701645C2 (hr) |
SG (2) | SG11201608502TA (hr) |
SI (1) | SI3137596T1 (hr) |
UA (1) | UA121656C2 (hr) |
WO (1) | WO2015168635A2 (hr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2839006B1 (en) * | 2012-04-20 | 2018-01-03 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
PT2992098T (pt) | 2013-05-01 | 2019-07-05 | Ionis Pharmaceuticals Inc | Composições e métodos para modular a expressão de hbv e ttr |
EP3043827B1 (en) * | 2013-09-13 | 2019-07-03 | Ionis Pharmaceuticals, Inc. | Modulators of complement factor b |
CA2942570A1 (en) | 2014-05-01 | 2015-11-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
PE20170010A1 (es) | 2014-05-01 | 2017-03-04 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion del factor b del complemento |
AU2015329974B2 (en) | 2014-10-10 | 2019-06-20 | F. Hoffmann-La Roche Ag | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use |
AU2016349625B2 (en) * | 2015-11-06 | 2022-07-07 | Ionis Pharmaceuticals, Inc. | Modulating apolipoprotein (a) expression |
IL291323B2 (en) | 2016-07-15 | 2023-09-01 | Am Chemicals Llc | Solid non-nucleoside supports and phosphoramidite building blocks for oligonucleotide synthesis |
JOP20190215A1 (ar) * | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
US20210060168A1 (en) | 2019-09-03 | 2021-03-04 | Arcturus Therapeutics, Inc. | Asialoglycoprotein receptor mediated delivery of therapeutically active conjugates |
IL297680A (en) * | 2020-04-30 | 2022-12-01 | Alnylam Pharmaceuticals Inc | IRNA compounds complement factor b (cfb) and methods of using them |
WO2023031359A1 (en) | 2021-09-02 | 2023-03-09 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell |
CN118302525A (zh) | 2021-10-29 | 2024-07-05 | 阿尔尼拉姆医药品有限公司 | 补体因子B(CFB)iRNA组合物及其使用方法 |
WO2024097861A1 (en) * | 2022-11-02 | 2024-05-10 | Ionis Pharmaceuticals, Inc. | Methods for modulating complement factor b expression |
Family Cites Families (297)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
DE3329892A1 (de) | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | Verfahren zur herstellung von oligonucleotiden |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
USRE34036E (en) | 1984-06-06 | 1992-08-18 | National Research Development Corporation | Data transmission using a transparent tone-in band system |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
US4751219A (en) | 1985-02-05 | 1988-06-14 | Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek | Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
DE3788914T2 (de) | 1986-09-08 | 1994-08-25 | Ajinomoto Kk | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere. |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
AU598946B2 (en) | 1987-06-24 | 1990-07-05 | Howard Florey Institute Of Experimental Physiology And Medicine | Nucleoside derivatives |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
WO1989005358A1 (en) | 1987-11-30 | 1989-06-15 | University Of Iowa Research Foundation | Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
EP0406309A4 (en) | 1988-03-25 | 1992-08-19 | The University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
DE69034150T2 (de) | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5457191A (en) | 1990-01-11 | 1995-10-10 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5859221A (en) | 1990-01-11 | 1999-01-12 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
EP0455905B1 (en) | 1990-05-11 | 1998-06-17 | Microprobe Corporation | Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
BR9106702A (pt) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals Inc | Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
DE69115702T2 (de) | 1990-08-03 | 1996-06-13 | Sterling Winthrop Inc | Verbindungen und verfahren zur unterdrückung der genexpression |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
JPH06505704A (ja) | 1990-09-20 | 1994-06-30 | ギリアド サイエンシズ,インコーポレイテッド | 改変ヌクレオシド間結合 |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
US5948903A (en) | 1991-01-11 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Synthesis of 3-deazapurines |
US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
ES2103918T3 (es) | 1991-10-17 | 1997-10-01 | Ciba Geigy Ag | Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios. |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
AU3222793A (en) | 1991-11-26 | 1993-06-28 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
ATE515510T1 (de) * | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
AU678769B2 (en) | 1992-07-27 | 1997-06-12 | Hybridon, Inc. | Oligonucleotide alkylphosphonothioates |
ES2086997T3 (es) | 1993-01-25 | 1996-07-01 | Hybridon Inc | Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos. |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
GB9304620D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Compounds |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
CA2159631A1 (en) | 1993-03-30 | 1994-10-13 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
WO1994022891A1 (en) | 1993-03-31 | 1994-10-13 | Sterling Winthrop Inc. | Oligonucleotides with amide linkages replacing phosphodiester linkages |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
CA2178729A1 (en) | 1993-12-09 | 1995-06-15 | Eric B. Kmiec | Compounds and methods for site-directed mutations in eukaryotic cells |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5681940A (en) * | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
US20030119724A1 (en) | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
CN1120707C (zh) | 1995-11-22 | 2003-09-10 | 约翰斯·霍普金斯大学 | 增强生物分子的细胞摄取的配体 |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US6620916B1 (en) | 1996-09-26 | 2003-09-16 | Ajinomoto Co., Inc. | Modified physiologically active proteins and medicinal compositions containing the same |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
USRE44779E1 (en) | 1997-03-07 | 2014-02-25 | Santaris Pharma A/S | Bicyclonucleoside and oligonucleotide analogues |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ/エス | オリゴヌクレオチド類似体 |
US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
US6166239A (en) | 1998-09-04 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide protecting groups |
WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
US20030064944A1 (en) * | 2001-06-21 | 2003-04-03 | Isis Pharmaceuticals Inc. | Antisense modulation of transforming growth factor beta receptor II expression |
CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
US20030170249A1 (en) | 1999-02-19 | 2003-09-11 | Hakomori Sen-Itiroh | Vaccines directed to cancer-associated carbohydrate antigens |
US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
KR20010112944A (ko) | 1999-04-21 | 2001-12-22 | 이곤 이 버그 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 방법 및조성물 |
AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
US6383812B1 (en) | 1999-05-28 | 2002-05-07 | Academia Sinica | Anti liver disease drug R-YEEE and method of synthesizing branched galactose-terminal glycoproteins |
US20080281041A1 (en) | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
US8541548B2 (en) | 1999-06-07 | 2013-09-24 | Arrowhead Madison Inc. | Compounds and methods for reversible modification of biologically active molecules |
JP4151751B2 (ja) | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
DE19935303A1 (de) * | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
US20020082227A1 (en) | 1999-09-30 | 2002-06-27 | Scott Henry | Use of oligonucleotides for inhibition of complement activation |
JP2003519231A (ja) | 1999-12-30 | 2003-06-17 | カー・ユ・ルーベン・リサーチ・アンド・ディベロップメント | シクロヘキセン核酸 |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US7491805B2 (en) * | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
AU2001282522A1 (en) | 2000-08-29 | 2002-03-13 | Takeshi Imanishi | Novel nucleoside analogs and oligonucleotide derivatives containing these analogs |
US6426220B1 (en) | 2000-10-30 | 2002-07-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of calreticulin expression |
KR20030074637A (ko) | 2000-12-01 | 2003-09-19 | 셀 웍스 인크. | 글리코실화/갈락토실화된 펩티드, 이관능기적 링커 , 및뉴클레오티드성 단량성/중합체의 접합체, 및 관련 조성물및 사용 방법 |
US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
US20030158403A1 (en) | 2001-07-03 | 2003-08-21 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
WO2003004602A2 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
US20030175906A1 (en) | 2001-07-03 | 2003-09-18 | Muthiah Manoharan | Nuclease resistant chimeric oligonucleotides |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030073623A1 (en) * | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
CA2459347C (en) | 2001-09-04 | 2012-10-09 | Exiqon A/S | Locked nucleic acid (lna) compositions and uses thereof |
US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US20100240730A1 (en) | 2002-02-20 | 2010-09-23 | Merck Sharp And Dohme Corp. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
AU2003274906A1 (en) | 2002-07-31 | 2004-02-16 | Nucleonics, Inc. | Double stranded rna structures and constructs, and methods for generating and using the same |
US8729036B2 (en) * | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
WO2004024757A2 (en) | 2002-09-11 | 2004-03-25 | Santaris Pharma A/S | Modified pna molecules |
EP1572964A4 (en) | 2002-10-18 | 2007-08-08 | Nucleonics Inc | STRUCTURES AND CONSTRUCTIONS OF DOUBLE STRANDED RNA AND METHODS FOR THEIR GENERATION AND USE |
AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
WO2004063208A1 (en) | 2003-01-09 | 2004-07-29 | Postech Foundation | New phosphoramidite compounds |
EP2239329A1 (en) | 2003-03-07 | 2010-10-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
WO2004103288A2 (en) | 2003-05-13 | 2004-12-02 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of preventing recurrent miscarriages |
WO2004101619A1 (ja) | 2003-05-15 | 2004-11-25 | Shionogi Co., Ltd. | 機能的糖ペプチドの合理的設計および合成 |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
ES2382807T3 (es) | 2003-08-28 | 2012-06-13 | Takeshi Imanishi | Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación |
EP1664299B1 (en) * | 2003-09-16 | 2009-05-13 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
AU2004274021B2 (en) | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
US7959919B2 (en) | 2003-11-19 | 2011-06-14 | Novelmed Therapeutics, Inc. | Method of inhibiting factor B-mediated complement activation |
US20060019941A1 (en) | 2003-12-23 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
JPWO2005061707A1 (ja) | 2003-12-24 | 2007-07-12 | 協和醗酵工業株式会社 | 癌細胞のEg5阻害剤に対する感受性を判定する方法 |
US20050244851A1 (en) | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
CA2561531C (en) | 2004-02-10 | 2017-05-02 | The Regents Of The University Of Colorado | Inhibition of factor b, the alternative complement pathway and methods related thereto |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
JPWO2005097155A1 (ja) | 2004-04-08 | 2008-02-28 | タカラバイオ株式会社 | 神経突起伸長誘導剤 |
WO2005121372A2 (en) | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
JP5192234B2 (ja) | 2004-08-10 | 2013-05-08 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 化学修飾オリゴヌクレオチド |
US20090203132A1 (en) | 2004-09-09 | 2009-08-13 | Swayze Eric E | Pyrrolidinyl groups for attaching conjugates to oligomeric compounds |
CA2580504C (en) | 2004-09-17 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
US20080261905A1 (en) | 2004-11-08 | 2008-10-23 | K.U. Leuven Research And Development | Modified Nucleosides for Rna Interference |
US20060148740A1 (en) | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
EP1841867A1 (en) | 2005-01-24 | 2007-10-10 | Avaris AB | COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY |
WO2007035759A1 (en) | 2005-09-19 | 2007-03-29 | Johnson & Johnson Pharmaceutical Research & Development L.L.C. | Modulation of glucocorticoid receptor expression |
CA2627686A1 (en) * | 2005-11-02 | 2007-05-18 | The Government Of The United States Of America, As Represented By The Se Cretary Of Health And Human Services | Method evolved for recognition and testing of age related macular degeneration (mert-armd) |
CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
AU2007258117B2 (en) * | 2006-05-05 | 2013-05-30 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
DK2066684T3 (da) | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5´-Modificerede bicycliske nukleinsyreanaloge |
CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
US8658211B2 (en) | 2006-08-18 | 2014-02-25 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
CA2663601C (en) * | 2006-09-22 | 2014-11-25 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
ATE540118T1 (de) | 2006-10-18 | 2012-01-15 | Isis Pharmaceuticals Inc | Antisense-verbindungen |
EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
EP2604284A1 (en) | 2007-02-16 | 2013-06-19 | KTB Tumorforschungsgesellschaft mbH | Receptor And Antigen Targeted Prodrug |
US20100120665A1 (en) | 2007-03-01 | 2010-05-13 | Advanced Vision Therapies, Inc. | Treatment of diseases characterized by inflammation |
JP2010519911A (ja) * | 2007-03-02 | 2010-06-10 | エムディーアールエヌエー,インコーポレイテッド | Myc遺伝子の発現を抑制するための核酸化合物およびその使用 |
AU2008242583B2 (en) | 2007-04-23 | 2013-10-10 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
WO2009003009A1 (en) | 2007-06-26 | 2008-12-31 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolidine as anti-infectives |
CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
JP5572090B2 (ja) | 2007-08-15 | 2014-08-13 | アイシス ファーマシューティカルズ, インコーポレーテッド | テトラヒドロピラン核酸類似体 |
US20090123928A1 (en) | 2007-10-11 | 2009-05-14 | The Johns Hopkins University | Genomic Landscapes of Human Breast and Colorectal Cancers |
WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
WO2009134487A2 (en) | 2008-01-31 | 2009-11-05 | Alnylam Pharmaceuticals, Inc. | Optimized methods for delivery of dsrna targeting the pcsk9 gene |
US8530640B2 (en) | 2008-02-07 | 2013-09-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
US20110130440A1 (en) | 2008-03-26 | 2011-06-02 | Alnylam Pharmaceuticals, Inc. | Non-natural ribonucleotides, and methods of use thereof |
WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
WO2009143369A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc. | Method of preparing nucleosides and analogs thereof without using chromatography |
EP2320925B1 (en) | 2008-07-10 | 2015-12-23 | Regenesance B.V. | Complement antagonists and uses thereof |
WO2010017509A1 (en) | 2008-08-07 | 2010-02-11 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression for the treatment of cns related disorders |
EP3587434A1 (en) | 2008-09-23 | 2020-01-01 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with click components for conjugation with ligands |
DK2361256T3 (da) | 2008-09-24 | 2013-07-01 | Isis Pharmaceuticals Inc | Cyclohexenyl-nukleinsyreanaloger |
US8501805B2 (en) | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
AU2009307677C1 (en) | 2008-10-20 | 2022-09-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
CN102264374B (zh) | 2008-10-24 | 2015-01-07 | Isis制药公司 | 5′和2′双取代的核苷和由其制备的低聚化合物 |
EP2358398A2 (en) | 2008-10-24 | 2011-08-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
KR102344392B1 (ko) | 2008-11-10 | 2021-12-28 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
AU2010208035B2 (en) | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
US8975389B2 (en) | 2009-03-02 | 2015-03-10 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
FR2943060B1 (fr) | 2009-03-13 | 2013-01-04 | Commissariat Energie Atomique | Agents chelatants d'ions metalliques, leurs procedes de preparation et leurs applications |
NZ621981A (en) | 2009-05-05 | 2015-09-25 | Tekmira Pharmaceuticals Corp | Lipid compositions |
EA201791744A3 (ru) | 2009-06-10 | 2018-07-31 | Арбутус Биофарма Корпорэйшн | Улучшенная липидная композиция |
US8273869B2 (en) | 2009-06-15 | 2012-09-25 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsRNA targeting the PCSK9 gene |
WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
US9512164B2 (en) | 2009-07-07 | 2016-12-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
WO2011017521A2 (en) | 2009-08-06 | 2011-02-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
WO2011038356A2 (en) | 2009-09-25 | 2011-03-31 | Johns Hopkins University | Novel liver-targeting agents and their synthesis |
AU2010306639B2 (en) | 2009-10-16 | 2017-02-16 | Glaxo Group Limited | HBV antisense inhibitors |
TWI388338B (zh) | 2009-10-26 | 2013-03-11 | Iner Aec Executive Yuan | 對聚合醣鏈進行放射標誌以作為肝受體造影劑之方法 |
TWI391144B (zh) | 2009-10-26 | 2013-04-01 | Iner Aec Executive Yuan | 一種定量肝殘餘功能的檢驗方法與其新穎肝受體造影檢驗藥劑 |
WO2011072290A2 (en) | 2009-12-11 | 2011-06-16 | The Regents Of The University Of Michigan | Targeted dendrimer-drug conjugates |
US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
EP3023495B1 (en) | 2010-02-24 | 2019-05-08 | Arrowhead Pharmaceuticals, Inc. | Compositions for targeted delivery of sirna |
WO2011115818A1 (en) | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
JP2013528665A (ja) | 2010-03-26 | 2013-07-11 | メルサナ セラピューティックス, インコーポレイテッド | ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法 |
US20130109817A1 (en) | 2010-03-26 | 2013-05-02 | Mersana Therapeutics, Inc. | Modified Polymers for Delivery of Polynucleotides, Method of Manufacture, and Methods of Use Thereof |
US9102938B2 (en) | 2010-04-01 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | 2′ and 5′ modified monomers and oligonucleotides |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
JP6005628B2 (ja) | 2010-04-28 | 2016-10-12 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物 |
MX343559B (es) | 2010-04-29 | 2016-11-10 | Ionis Pharmaceuticals Inc | Modulacion de la expresion de transtiretina. |
US20130236968A1 (en) | 2010-06-21 | 2013-09-12 | Alnylam Pharmaceuticals, Inc. | Multifunctional copolymers for nucleic acid delivery |
US9290760B2 (en) | 2010-09-15 | 2016-03-22 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
WO2012068187A1 (en) | 2010-11-19 | 2012-05-24 | Merck Sharp & Dohme Corp. | Poly(amide) polymers for the delivery of oligonucleotides |
MX346144B (es) | 2010-12-17 | 2017-03-09 | Arrowhead Res Corp * | Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi. |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
CA3131967A1 (en) | 2010-12-29 | 2012-07-05 | F. Hoffman-La Roche Ag | Small molecule conjugates for intracellular delivery of nucleic acids |
EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
PL2697243T3 (pl) | 2011-04-01 | 2019-05-31 | Ionis Pharmaceuticals Inc | Modulacja ekspresji przekaźnika sygnału i aktywatora transkrypcji 3 (stat3) |
TW201303013A (zh) | 2011-04-21 | 2013-01-16 | Isis Pharmaceuticals Inc | B型肝炎病毒(hbv)表現之調節 |
SI3505528T1 (sl) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
CN112961855A (zh) | 2011-06-21 | 2021-06-15 | 阿尔尼拉姆医药品有限公司 | 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法 |
RU2631805C2 (ru) * | 2011-06-21 | 2017-09-26 | Элнилэм Фармасьютикалз, Инк. | Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3) |
US8932572B2 (en) | 2011-08-26 | 2015-01-13 | Arrowhead Madison Inc. | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
DK2751270T3 (en) | 2011-08-29 | 2018-10-29 | Ionis Pharmaceuticals Inc | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE |
SI3301177T1 (sl) * | 2011-11-18 | 2020-07-31 | Alnylam Pharmaceuticals, Inc. | Sredstva RNAi, sestavki in postopki njihove uporabe za zdravljenje s transtiretinom (TTR) povezanih bolezni |
WO2013119979A1 (en) | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating factor vii expression |
EP2839006B1 (en) | 2012-04-20 | 2018-01-03 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
TWI595885B (zh) * | 2012-05-02 | 2017-08-21 | 喜納製藥公司 | 包含四galnac之新穎結合物及傳送寡核苷酸之方法 |
WO2013173789A2 (en) | 2012-05-17 | 2013-11-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
EP2906699A4 (en) | 2012-10-11 | 2016-06-08 | Ionis Pharmaceuticals Inc | OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF |
CN104884618A (zh) | 2012-11-15 | 2015-09-02 | 罗氏创新中心哥本哈根有限公司 | 寡核苷酸缀合物 |
CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
CN114015692A (zh) * | 2013-03-14 | 2022-02-08 | 阿尔尼拉姆医药品有限公司 | 补体组分C5 iRNA组合物及其使用方法 |
PT2992098T (pt) | 2013-05-01 | 2019-07-05 | Ionis Pharmaceuticals Inc | Composições e métodos para modular a expressão de hbv e ttr |
US20160122761A1 (en) * | 2013-06-21 | 2016-05-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
LT3013959T (lt) | 2013-06-27 | 2020-03-10 | Roche Innovation Center Copenhagen A/S | Priešprasmiai oligomerai ir konjugatai, nukreirti į pcsk9 |
DE102013106985A1 (de) * | 2013-07-03 | 2015-01-22 | Osram Oled Gmbh | Optoelektronische Bauelementevorrichtung und Verfahren zum Herstellen einer optoelektronischen Bauelementevorrichtung |
DK3019200T3 (da) * | 2013-07-11 | 2022-06-20 | Alnylam Pharmaceuticals Inc | Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf |
EP3043827B1 (en) * | 2013-09-13 | 2019-07-03 | Ionis Pharmaceuticals, Inc. | Modulators of complement factor b |
CN105814205B (zh) * | 2013-12-12 | 2019-11-19 | 阿尔尼拉姆医药品有限公司 | 补体成分iRNA组合物及其使用方法 |
PE20170010A1 (es) | 2014-05-01 | 2017-03-04 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion del factor b del complemento |
-
2015
- 2015-05-01 PE PE2016002157A patent/PE20170010A1/es unknown
- 2015-05-01 KR KR1020167032652A patent/KR102369736B1/ko active IP Right Grant
- 2015-05-01 JP JP2016565465A patent/JP6637442B2/ja active Active
- 2015-05-01 SI SI201530821T patent/SI3137596T1/sl unknown
- 2015-05-01 PT PT15786214T patent/PT3137596T/pt unknown
- 2015-05-01 EA EA201692204A patent/EA036496B1/ru unknown
- 2015-05-01 ES ES19184459T patent/ES2941742T3/es active Active
- 2015-05-01 ES ES15786214T patent/ES2745825T3/es active Active
- 2015-05-01 RS RSP20191141 patent/RS59182B1/sr unknown
- 2015-05-01 US US15/307,526 patent/US10280423B2/en active Active
- 2015-05-01 PL PL19184459.6T patent/PL3608406T3/pl unknown
- 2015-05-01 EP EP15786214.5A patent/EP3137596B1/en active Active
- 2015-05-01 CR CR20200228A patent/CR20200228A/es unknown
- 2015-05-01 RU RU2016147047A patent/RU2701645C2/ru active
- 2015-05-01 CR CR20160554A patent/CR20160554A/es unknown
- 2015-05-01 BR BR112016022593-7A patent/BR112016022593B1/pt active IP Right Grant
- 2015-05-01 CN CN201910898718.XA patent/CN110724687B/zh active Active
- 2015-05-01 HU HUE15786214A patent/HUE046272T2/hu unknown
- 2015-05-01 MX MX2016014294A patent/MX2016014294A/es unknown
- 2015-05-01 EP EP23154909.8A patent/EP4219718A3/en active Pending
- 2015-05-01 AU AU2015252858A patent/AU2015252858C1/en active Active
- 2015-05-01 SG SG11201608502TA patent/SG11201608502TA/en unknown
- 2015-05-01 CA CA2943894A patent/CA2943894A1/en active Pending
- 2015-05-01 UA UAA201612124A patent/UA121656C2/uk unknown
- 2015-05-01 DK DK15786214.5T patent/DK3137596T3/da active
- 2015-05-01 SG SG10201809953QA patent/SG10201809953QA/en unknown
- 2015-05-01 PE PE2019000234A patent/PE20190626A1/es unknown
- 2015-05-01 EP EP19184459.6A patent/EP3608406B1/en active Active
- 2015-05-01 LT LTEP15786214.5T patent/LT3137596T/lt unknown
- 2015-05-01 CN CN201580020852.XA patent/CN106232804B/zh active Active
- 2015-05-01 WO PCT/US2015/028916 patent/WO2015168635A2/en active Application Filing
- 2015-05-01 PL PL15786214T patent/PL3137596T3/pl unknown
-
2016
- 2016-09-18 IL IL247883A patent/IL247883B/en active IP Right Grant
- 2016-10-17 PH PH12016502062A patent/PH12016502062A1/en unknown
- 2016-10-28 DO DO2016000291A patent/DOP2016000291A/es unknown
- 2016-11-02 CL CL2016002764A patent/CL2016002764A1/es unknown
-
2018
- 2018-07-23 CL CL2018001996A patent/CL2018001996A1/es unknown
-
2019
- 2019-03-18 US US16/357,018 patent/US20200048638A1/en not_active Abandoned
- 2019-09-16 HR HRP20191664 patent/HRP20191664T1/hr unknown
- 2019-12-19 JP JP2019228789A patent/JP7001663B2/ja active Active
- 2019-12-23 IL IL271659A patent/IL271659A/en unknown
-
2021
- 2021-05-07 US US17/314,537 patent/US11732265B2/en active Active
-
2023
- 2023-05-19 US US18/320,948 patent/US20230357776A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191664T1 (hr) | Sastavi i postupci za moduliranje ekspresije komplementa faktora b | |
HRP20191600T1 (hr) | Modulatori faktora b komplementa | |
HRP20200843T1 (hr) | Sastavi za moduliranje ekspresije c9orf72 | |
HRP20201378T1 (hr) | Pripravci i postupci za modulaciju ekspresije apolipoproteina (a) | |
HRP20201426T1 (hr) | Postupci i pripravci za moduliranje ekspresije apolipoproteina (a) | |
GT200600221A (es) | Tigeciclina y metodos de preparacion | |
RU2016116849A (ru) | Композиции для модуляции экспрессии c90rf72 | |
HRP20070342A2 (hr) | Derivati indola za liječenje virusnih infekcija | |
GT200600224A (es) | Metodos para purificar tigeciclina | |
ME00997B (me) | 2'-fluor-2 ' -deoksitetrahidrouridini kao inhibitori citidin deaminaze | |
NO20082125L (no) | Substituerte benzokondenserte derivater og deres anvendelse som vanilloidreseptorligander | |
FR2926553B1 (fr) | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique | |
CL2007001969A1 (es) | Compuestos derivados de ciclobuten-1,2-dionas-3,4-disustituidas, ligandos de receptores de quimiocinas cxc; composicion farmaceutica; y su uso para tratar enfermedades mediadas por quimiocinas, tales como cancer, gingivitis, virus respiratorios, entre otras. | |
PH12015502220A1 (en) | Packet-level splitting for data transmission via multiple carriers | |
EA200601897A1 (ru) | Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора н3 гистамина | |
HRP20070043A2 (hr) | Antivirusna sredstva | |
ECSP10010226A (es) | Compuestos derivados de amina para tratar enfermedades y trastornos oftálmicos | |
MX2015011779A (es) | Nucleosidos biciclicos unidos en puente. | |
BR112013032771A2 (pt) | dipeptídio quimicamente e metabolicamente estável possuindo potente atividade bloqueadora de canais de sódio | |
HRP20231606T1 (hr) | Spojevi i metode za smanjenje ekspresije tau | |
MX2009011205A (es) | Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide. | |
EA200870514A1 (ru) | Ацетиленовые гетероарильные соединения | |
EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
EA201790234A1 (ru) | 2'-хлораминопиримидиноновые и пиримидиндионовые нуклеозиды | |
FR2903404B1 (fr) | Nouveaux derives tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |